Alamar Biosciences - Class A (ALMR) closed at $30.22 on November 3, 2026, up 4.4% from the previous close, on volume of 644,407 shares (30-day average 712,838).
Data as of November 3, 2026.
Alamar Biosciences, Inc. GAAP EPS of -$0.19 beats by $0.03, revenue of $33.5M beats by $3.31M
Seeking Alpha News (Tue, 3-Nov 4:36 PM ET)
Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
Globe Newswire (Tue, 3-Nov 4:05 PM ET)
Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine
Globe Newswire (Tue, 3-Nov 4:03 PM ET)
Globe Newswire (Mon, 2-Nov 7:05 PM ET)
Globe Newswire (Mon, 2-Nov 8:00 AM ET)
Globe Newswire (Wed, 28-Oct 4:05 PM ET)
Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026
Globe Newswire (Thu, 8-Oct 4:05 PM ET)
Globe Newswire (Mon, 5-Oct 4:05 PM ET)
Globe Newswire (Thu, 24-Sep 6:51 PM ET)
Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
Globe Newswire (Tue, 1-Sep 4:05 PM ET)
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
Alamar Biosciences - Class A trades on the NASDAQ stock market under the symbol ALMR.
As of November 3, 2026, ALMR stock price climbed to $30.22 with 644,407 million shares trading.
ALMR has a beta of -1.06, meaning it tends to be less sensitive to market movements. ALMR has a correlation of 0.02 to the broad based SPY ETF.
ALMR has a market cap of $2.10 billion. This is considered a Mid Cap stock.
Last quarter Alamar Biosciences - Class A reported $29 million in Revenue and -$.22 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.11.
The top ETF exchange traded funds that ALMR belongs to (by Net Assets): ARKG, VTI, IWM, VXF, VTWO.
ALMR support price is $26.99 and resistance is $30.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALMR shares will trade within this expected range on the day.
